A5026985874- Lysosomal Storage Disorders Research
- Genetic Syndromes and Imprinting
- Cell Adhesion Molecules Research
- Cellular transport and secretion
- Calcium signaling and nucleotide metabolism
- Immune Response and Inflammation
- Analytical Chemistry and Sensors
- Nanoparticle-Based Drug Delivery
- Platelet Disorders and Treatments
- Carbohydrate Chemistry and Synthesis
- Clinical Nutrition and Gastroenterology
- RNA Interference and Gene Delivery
- Caveolin-1 and cellular processes
- Sepsis Diagnosis and Treatment
- Biochemical and Structural Characterization
- Advanced Fluorescence Microscopy Techniques
- Autoimmune and Inflammatory Disorders Research
- Nanoplatforms for cancer theranostics
- Electrolyte and hormonal disorders
- Complement system in diseases
- Epigenetics and DNA Methylation
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Intensive Care Unit Cognitive Disorders
- Immune cells in cancer
- Sphingolipid Metabolism and Signaling
Universidad de Sevilla
2009-2024
University of Maryland, College Park
2010-2014
Institute for Bioscience and Biotechnology Research
2012
Biotechnology Institute
2010
University of Pennsylvania
2005-2008
Institute for Environmental Management
2008
Morgan, Lewis & Bockius (United States)
2008
Hospital Universitario Virgen del Rocío
2001-2004
Hospital Universitario Virgen Macarena
2000
Endocytosis in endothelial cells (ECs) is important for many biomedical applications, including drug delivery by nano- and microscale carriers. However, little known about how carrier geometry influences targeting, intracellular trafficking, effects. We studied this using prototype polymer carriers of various sizes (0.1-10 mum) shapes (spheres versus elliptical disks). Carriers were targeted to intercellular adhesion molecule 1 (ICAM-1), a transmembrane glycoprotein that upregulated...
High-resolution images of oxygen distributions in microheterogeneous samples are obtained by two-photon laser scanning microscopy (2P LSM), using a newly developed dendritic nanoprobe with internally enhanced absorption (2PA) cross-section. In this probe, energy is harvested 2PA antenna, which passes excitation onto phosphorescent metalloporphyrin via intramolecular transfer. The 2P LSM allows sectioning gradients near diffraction-limited resolution, and lifetime-based acquisition eliminates...
Abstract Introduction Genetic variations may influence clinical outcomes in patients with sepsis. The present study was conducted to evaluate the impact on mortality of three polymorphisms after adjusting for confounding variables, and assess factors involved progression inflammatory response septic patients. Method inception cohort included all Caucasian adults admitted hospital Sepsis severity, microbiological information variables were recorded. Three identified by PCR: tumour necrosis...
Cancer is a complex disease that, despite advances in treatment and the greater understanding of tumor biology until today, continues to be prevalent lethal disease. Chemotherapy, radiotherapy, surgery are conventional treatments, which have increased survival for cancer patients. However, complexity this together with persistent problems due progression recurrence, drug resistance, or side effects therapy make it necessary explore new strategies that address challenges obtain positive...
Type B Niemann-Pick disease (NPD) is a multiorgan system disorder caused by genetic deficiency of acid sphingomyelinase (ASM), for which lung an important and challenging therapeutic target. In this study, we designed evaluated new delivery vehicles enzyme replacement therapy type NPD, consisting polystyrene poly(lactic-coglycolic) polymer nanocarriers targeted to intercellular adhesion molecule (ICAM)-1, endothelial surface protein up-regulated in many pathologies, including NPD. Real-time...
Objective— Engagement of intercellular adhesion molecule 1 (ICAM-1) on endothelial cells by ICAM-1-targeted carriers induces cell molecule–mediated endocytosis, providing intraendothelial delivery therapeutics. This pathway differs from classical endocytic mechanisms and invokes aspects signaling during inflammation. ICAM-1 interacts with Na + /H exchanger NHE1 but it is unclear how this regulates plasmalemma cytoskeletal changes. We studied such in work. Methods Results— used fluorescence...
Many cellular activities and pharmaceutical interventions involve endocytosis delivery to lysosomes for processing. Hence, lysosomal processing defects can cause cell tissue damage, as in storage diseases (LSDs) characterized by accumulation of undegraded materials. This causes endocytic trafficking alterations, which exacerbate disease hinder treatment. However, there have been no systematic studies comparing different routes LSDs. Here, we used genetic pharmacological models four LSDs...
Acid sphingomyelinase deficiency in type B Niemann-Pick disease leads to lysosomal sphingomyelin storage, principally affecting lungs, liver, and spleen. Infused recombinant enzyme is beneficial, yet its delivery the lungs limited requires higher dosing than liver spleen, leading potentially adverse reactions. Previous studies showed increased pulmonary uptake by nanocarriers targeted ICAM-1, a protein overexpressed during inflammation. Here, using polystyrene poly(lactic-co-glycolic acid)...
Intercellular adhesion molecule-1 (ICAM-1), a transmembrane glycoprotein expressed on activated endothelium and many other cells, represents suitable target for delivery of drug nanocarriers (NCs) to disease areas. Numerous works have shown efficient targeting intracellular transport ICAM-1-targeted NCs, rendering significant therapeutic potential. This is the case enzyme treatment multitissue lysosomal storage disorders. However, those studies used formulations targeted ICAM-1 by antibodies...
Drugs often use endocytosis to achieve intracellular delivery, either by passive uptake from the extracellular fluid or active targeting of cell surface features such as endocytic receptors. An example is enzyme replacement therapy, a clinically practiced treatment for several lysosomal storage diseases where glycosylated recombinant enzymes naturally target mannose-6-phosphate receptor and are internalized clathrin mediated (CME). However, substrate accumulation, hallmark these diseases,...
Pharmaceutical intervention often requires therapeutics and/or their carriers to enter cells via endocytosis. Therefore, endocytic aberrancies resulting from disease represent a key, yet overlooked, parameter in designing therapeutic strategies. In the case of lysosomal storage diseases (LSDs), characterized by accumulation undegraded substances, common clinical interventions rely on endocytosis recombinant enzymes. However, defect these can affect endocytosis, as we recently demonstrated...